If you are looking to add some ASX 200 stocks to your portfolio this week, it could be worth checking out the two in this article.
That's because Bell Potter believes they could be dirt cheap at current levels. Here's what the broker is recommending:
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
The first ASX 200 stock that Bell Potter is bullish on is Pro Medicus.
It likes the health imaging technology company due to favourable industry trends and the quality of its Visage platform.
The broker explains:
The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.
The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.
Bell Potter has a buy rating and $240.00 price target on its shares. This implies potential upside of 100% for investors over the next 12 months.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 stock that Bell Potter is recommending to clients is Telix.
It is a radiopharmaceuticals company that had a tough time in 2025 with US FDA rejections. However, the broker appears to believe that 2026 could be different, potentially making now a good time to invest.
Bell Potter commented:
We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix's manufacturing partner. There were no matters related to safety or efficacy. We expect the market for Zircaix once approved will be in excess of US$500m.
The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.
The broker has a buy rating and $19.00 price target on Telix's shares. This suggests that they could rise approximately 50% from current levels.
